These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38548067)

  • 1. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
    Castera L; Garteiser P; Laouenan C; Vidal-Trécan T; Vallet-Pichard A; Manchon P; Paradis V; Czernichow S; Roulot D; Larger E; Pol S; Bedossa P; Correas JM; Valla D; Gautier JF; Van Beers BE;
    J Hepatol; 2024 Aug; 81(2):195-206. PubMed ID: 38548067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.
    Kim BK; Tamaki N; Imajo K; Yoneda M; Sutter N; Jung J; Lin T; Tu XM; Bergstrom J; Nguyen K; Nguyen L; Le T; Madamba E; Richards L; Valasek MA; Behling C; Sirlin CB; Nakajima A; Loomba R
    J Hepatol; 2022 Dec; 77(6):1482-1490. PubMed ID: 35973577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis.
    Qi S; Wei X; Zhao J; Wei X; Guo H; Hu J; WuYun Q; Pan CQ; Zhang N; Zhang J
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1656-1662. PubMed ID: 38686620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Tamaki N; Imajo K; Sharpton S; Jung J; Kawamura N; Yoneda M; Valasek MA; Behling C; Sirlin CB; Nakajima A; Loomba R
    Hepatology; 2022 Mar; 75(3):661-672. PubMed ID: 34496054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
    Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
    J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
    Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
    World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
    Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
    PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
    Poynard T; Deckmyn O; Peta V; Paradis V; Gautier JF; Brzustowski A; Bedossa P; Castera L; Pol S; Valla D;
    Aliment Pharmacol Ther; 2023 Nov; 58(9):888-902. PubMed ID: 37642160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD).
    Albert SG; Wood EM
    J Diabetes Complications; 2024 Jul; 38(7):108777. PubMed ID: 38788522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
    J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score.
    Marti-Aguado D; Arnouk J; Liang JX; Lara-Romero C; Behari J; Furlan A; Jimenez-Pastor A; Ten-Esteve A; Alfaro-Cervello C; Bauza M; Gallen-Peris A; Gimeno-Torres M; Merino-Murgui V; Perez-Girbes A; Benlloch S; Pérez-Rojas J; Puglia V; Ferrández-Izquierdo A; Aguilera V; Giesteira B; França M; Monton C; Escudero-García D; Alberich-Bayarri Á; Serra MA; Bataller R; Romero-Gomez M; Marti-Bonmati L
    Liver Int; 2024 Jan; 44(1):202-213. PubMed ID: 37904633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FAST and Agile-the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin.
    Taru MG; Tefas C; Neamti L; Minciuna I; Taru V; Maniu A; Rusu I; Petrushev B; Procopciuc LM; Leucuta DC; Procopet B; Ferri S; Lupsor-Platon M; Stefanescu H
    PLoS One; 2024; 19(5):e0303971. PubMed ID: 38781158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
    Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
    Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis.
    Ravaioli F; Dajti E; Mantovani A; Newsome PN; Targher G; Colecchia A
    Gut; 2023 Jul; 72(7):1399-1409. PubMed ID: 36599683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
    De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
    J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study.
    Cui J; Ang B; Haufe W; Hernandez C; Verna EC; Sirlin CB; Loomba R
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1271-80. PubMed ID: 25873207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the efficacy of 8 non-invasive models in predicting MASLD and progression: a prospective study.
    Yang A; Zhu X; Zhang L; Zhang D; Jin M; Lv G; Ding Y
    BMC Gastroenterol; 2024 Oct; 24(1):365. PubMed ID: 39402469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms.
    Papatheodoridi M; De Ledinghen V; Lupsor-Platon M; Bronte F; Boursier J; Elshaarawy O; Marra F; Thiele M; Markakis G; Payance A; Brodkin E; Castera L; Papatheodoridis G; Krag A; Arena U; Mueller S; Cales P; Calvaruso V; Delamarre A; Pinzani M; Tsochatzis EA
    J Hepatol; 2024 Oct; 81(4):590-599. PubMed ID: 38789011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.